| Name | Title | Contact Details |
|---|
ContextVision is a leading provider of medical image enhancement software to global equipment manufacturers. With its versatile GOP® technology at the core of its extensive product line, ContextVision enables its customers to offer clinicians unparalleled diagnostic image quality, ultimately providing patients with better care. ContextVision was established in 1983 by a specialist research team at Linköping University in Sweden. The university has been a center for digital image research and analysis. ContextVision, now considered the gold standard of medical image enhancement, offers a powerful combination of sophisticated technology and team expertise within ultrasound, x-ray, magnetic resonance imaging, mammography, interventional radiology and computed tomography. More than 150,000 systems across the globe rely on ContextVision`s market-leading products for 2D, 3D, or 4D image enhancements. Its dynamic group of image-enhancement experts customize installations for optimal image quality.
BSN medical is a global medical device company specializing in the areas of Orthopaedics which focuses on bandaging, cast tapes, Plaster of Paris, splinting systems, orthopaedic soft goods, fracture bracing, and thermoplastics, Phlebology which serves
Orqis Medical Corporation is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ActiveCare, Inc. provides patented diabetes and chronic disease management and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease.
In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.